Market Research Logo

Chronic Cough - Pipeline Review, H2 2015

Chronic Cough - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chronic cough - Pipeline Review, H2 2015’, provides an overview of the Chronic cough’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic cough and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic cough
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic cough and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic cough pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic cough
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic cough pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chronic Cough Overview
Therapeutics Development
Pipeline Products for Chronic Cough - Overview
Chronic Cough - Therapeutics under Development by Companies
Chronic Cough - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Chronic Cough - Products under Development by Companies
Chronic Cough - Companies Involved in Therapeutics Development
Afferent Pharmaceuticals, Inc.
Ario Pharma Ltd
AstraZeneca Plc
Conrig Pharma ApS
Glenmark Pharmaceuticals Ltd.
Patara Pharma, Inc.
Chronic Cough - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AF-219 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC-17536 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lesogaberan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ST-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XEND-0501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Cough - Recent Pipeline Updates
Chronic Cough - Dormant Projects
Chronic Cough - Discontinued Products
Chronic Cough - Product Development Milestones
Featured News & Press Releases
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Cough, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
Chronic Cough - Pipeline by Ario Pharma Ltd, H2 2015
Chronic Cough - Pipeline by AstraZeneca Plc, H2 2015
Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2015
Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chronic Cough Therapeutics - Recent Pipeline Updates, H2 2015
Chronic Cough - Dormant Projects, H2 2015
Chronic Cough - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chronic Cough, H2 2015
Number of Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report